Stockreport

Publication of Results from Pivotal FOCUS Study in Metastatic Uveal Melanoma Patients treated with HEPZATO KIT [Yahoo! Finance]

Delcath Systems, Inc.  (DCTH) 
US:NASDAQ Investor Relations: delcath.com/investors
PDF Other Efficacy Endpoints Include a 73.6% Disease Control Rate with a 7.7% Complete Response Rate NEW YORK May 6, 2024 /PRNewswire/ -- Delcath Systems, Inc. (Nasdaq: D [Read more]